209 related articles for article (PubMed ID: 33298453)
1. Integration of intra-sample contextual error modeling for improved detection of somatic mutations from deep sequencing.
Abelson S; Zeng AGX; Nofech-Mozes I; Wang TT; Ng SWK; Minden MD; Pugh TJ; Awadalla P; Shlush LI; Murphy T; Chan SM; Dick JE; Bratman SV
Sci Adv; 2020 Dec; 6(50):. PubMed ID: 33298453
[TBL] [Abstract][Full Text] [Related]
2. Accurate and Sensitive Analysis of Minimal Residual Disease in Acute Myeloid Leukemia Using Deep Sequencing of Single Nucleotide Variations.
Delsing Malmberg E; Rehammar A; Pereira MB; Abrahamsson J; Samuelsson T; Ståhlman S; Asp J; Tierens A; Palmqvist L; Kristiansson E; Fogelstrand L
J Mol Diagn; 2019 Jan; 21(1):149-162. PubMed ID: 30273780
[TBL] [Abstract][Full Text] [Related]
3. Clinical Validation and Implementation of a Measurable Residual Disease Assay for NPM1 in Acute Myeloid Leukemia by Error-Corrected Next-Generation Sequencing.
Ritterhouse LL; Parilla M; Zhen CJ; Wurst MN; Puranik R; Henderson CM; Joudeh NZ; Hartley MJ; Haridas R; Wanjari P; Furtado LV; Kadri S; Segal JP
Mol Diagn Ther; 2019 Dec; 23(6):791-802. PubMed ID: 31673932
[TBL] [Abstract][Full Text] [Related]
4. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
[TBL] [Abstract][Full Text] [Related]
5. Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing.
Balagopal V; Hantel A; Kadri S; Steinhardt G; Zhen CJ; Kang W; Wanjari P; Ritterhouse LL; Stock W; Segal JP
PLoS One; 2019; 14(10):e0224097. PubMed ID: 31658273
[TBL] [Abstract][Full Text] [Related]
6. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
7. Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.
Malmberg EB; Ståhlman S; Rehammar A; Samuelsson T; Alm SJ; Kristiansson E; Abrahamsson J; Garelius H; Pettersson L; Ehinger M; Palmqvist L; Fogelstrand L
Eur J Haematol; 2017 Jan; 98(1):26-37. PubMed ID: 27197529
[TBL] [Abstract][Full Text] [Related]
8. Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML.
Stasik S; Burkhard-Meier C; Kramer M; Middeke JM; Oelschlaegel U; Sockel K; Ehninger G; Serve H; Müller-Tidow C; Baldus CD; Röllig C; Bornhäuser M; Platzbecker U; Thiede C
Blood Adv; 2022 Jun; 6(11):3294-3303. PubMed ID: 35320339
[TBL] [Abstract][Full Text] [Related]
9. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
Yang F; Anekpuritanang T; Press RD
Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
[TBL] [Abstract][Full Text] [Related]
10. Clinical value of molecular MRD monitoring by next-generation sequencing in patients with
Shumilov E; Flach J; Joncourt R; Porret N; Wiedemann G; Novak U; Gfeller E; Jeker B; Amstutz U; Pabst T; Bacher U
Leuk Lymphoma; 2019 Oct; 60(10):2588-2590. PubMed ID: 30998101
[No Abstract] [Full Text] [Related]
11. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
Press RD; Eickelberg G; Froman A; Yang F; Stentz A; Flatley EM; Fan G; Lim JY; Meyers G; Maziarz RT; Cook RJ
Am J Hematol; 2019 Aug; 94(8):902-912. PubMed ID: 31124175
[TBL] [Abstract][Full Text] [Related]
12. Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia.
Hirsch P; Tang R; Abermil N; Flandrin P; Moatti H; Favale F; Suner L; Lorre F; Marzac C; Fava F; Mamez AC; Lapusan S; Isnard F; Mohty M; Legrand O; Douay L; Bilhou-Nabera C; Delhommeau F
Haematologica; 2017 Jul; 102(7):1227-1237. PubMed ID: 28302711
[TBL] [Abstract][Full Text] [Related]
13. A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia.
Onecha E; Linares M; Rapado I; Ruiz-Heredia Y; Martinez-Sanchez P; Cedena T; Pratcorona M; Oteyza JP; Herrera P; Barragan E; Montesinos P; Vela JAG; Magro E; Anguita E; Figuera A; Riaza R; Martinez-Barranco P; Sanchez-Vega B; Nomdedeu J; Gallardo M; Martinez-Lopez J; Ayala R
Haematologica; 2019 Feb; 104(2):288-296. PubMed ID: 30093399
[TBL] [Abstract][Full Text] [Related]
14. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring.
Luthra R; Patel KP; Reddy NG; Haghshenas V; Routbort MJ; Harmon MA; Barkoh BA; Kanagal-Shamanna R; Ravandi F; Cortes JE; Kantarjian HM; Medeiros LJ; Singh RR
Haematologica; 2014 Mar; 99(3):465-73. PubMed ID: 24142997
[TBL] [Abstract][Full Text] [Related]
15. The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemia.
Bewersdorf JP; Shallis RM; Boddu PC; Wood B; Radich J; Halene S; Zeidan AM
Blood Rev; 2020 Sep; 43():100650. PubMed ID: 31883804
[TBL] [Abstract][Full Text] [Related]
16. Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia.
Dillon LW; Hayati S; Roloff GW; Tunc I; Pirooznia M; Mitrofanova A; Hourigan CS
Haematologica; 2019 Feb; 104(2):297-304. PubMed ID: 30171026
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia.
Aitken MJL; Ravandi F; Patel KP; Short NJ
J Hematol Oncol; 2021 Sep; 14(1):137. PubMed ID: 34479626
[TBL] [Abstract][Full Text] [Related]
18. The role of next-generation sequencing in acute myeloid leukemia.
Llop M; Sargas C; Barragán E
Curr Opin Oncol; 2022 Nov; 34(6):723-728. PubMed ID: 36102349
[TBL] [Abstract][Full Text] [Related]
19. Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions.
Selim AG; Moore AS
J Mol Diagn; 2018 Jul; 20(4):389-397. PubMed ID: 29689379
[TBL] [Abstract][Full Text] [Related]
20. Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients.
Zuffa E; Franchini E; Papayannidis C; Baldazzi C; Simonetti G; Testoni N; Abbenante MC; Paolini S; Sartor C; Parisi S; Marconi G; Cattina F; Bochicchio MT; Venturi C; Ottaviani E; Cavo M; Martinelli G
Oncotarget; 2015 Oct; 6(31):31284-94. PubMed ID: 26384303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
